

Detection of Early Neurochemical Changes related to Neurodegeneration in a Spinocerebellar Ataxia Type 1 (SCA1) Mouse Model by ^1H MRS at 9.4 Tesla

U. E. Emir¹, H. B. Clark¹, M. Vollmers¹, D. M. Koski¹, L. E. Eberly¹, H. T. Orr¹, H. Y. Zoghbi², and G. Oz¹
¹University of Minnesota, Minneapolis, MN, United States, ²Baylor College of Medicine, Houston, TX, United States

Introduction

Hereditary spinocerebellar ataxias (SCAs) are a clinically and genetically heterogeneous group of neurodegenerative diseases characterized by loss of cerebellar Purkinje cells (PC) (1). The sensitivity of MRS biomarkers (NAA, glutamate, *myo*-inositol) to progressive neurodegeneration was previously reported in a transgenic mouse model of SCA1 (2). In that model, neuronal dysfunction apparent as dendritic atrophy started at 6 weeks and neurodegeneration progressed to severe pathology by one year. In order to identify MRS biomarkers of even earlier pathology, here we utilized a knockin mouse model of SCA1: The *Sca1*^{154Q/2Q} line has a 154 polyglutamine repeat in the endogenous ataxin-1 protein (3) and presents with milder cerebellar pathology than the transgenic SCA1 mice studied before. We hypothesized that MRS biomarkers would be sensitive to disease even prior to the development of clear pathological changes and compared cerebellar neurochemical profiles of *Sca1*^{154Q/2Q} mice longitudinally to those of wild type (WT) littermates to test this hypothesis.

Methods

Two groups of mice (*Sca1*^{154Q/2Q} knockin mice, N=10, and WT littermates, N = 9) were scanned at 9.4 tesla under 1.5 - 2% isoflurane anesthesia at ages 6, 12, 24 and 39 weeks with a quadrature surface coil. Spectra from the cerebellum (5 - 7 μL volumes) were acquired with a short-echo (TE = 15 ms) LASER sequence (4). Metabolites were quantified with LCModel (5) using unsuppressed water as reference. The LCModel basis set was generated with the MATLAB software by simulating the spectral pattern of each metabolite using density matrix simulations (6). Only results with Cramér-Rao lower bounds (CRLB) $\leq 50\%$ were included in the analysis. A subset of the animals at each age was evaluated by histology performed on paraffin-embedded sections using hematoxylin-and-eosin and calbindin. *Sca1*^{154Q/2Q} were compared to WT at each age using the two-tailed student's t-test.

Results and Discussion

High spectral quality (Fig. 1) enabled reliable quantification of 18 metabolites. Four MRS biomarkers of early cerebellar neurodegeneration (taurine, total choline (tCho), glutamine and total creatine (tCr)) were identified (Fig. 2). Taurine was significantly lower in *Sca1*^{154Q/2Q} mice than controls at all ages. tCho was lower and glutamine higher for *Sca1*^{154Q/2Q} mice starting at 12 weeks, whereas tCr showed a trend to increase at 12 weeks, which became significant at 39 weeks. Taurine vs. tCho levels distinguished the *Sca1*^{154Q/2Q} mice from controls starting at 12 weeks (Fig. 3). Taurine changes may represent osmolytic changes while increased glutamine and creatine may mark glial hypertrophy/hyperplasia. Although trends were observed for the neuronal markers NAA and glutamate to decrease in the *Sca1*^{154Q/2Q} mice relative to WT, cerebellar disease did not reach a severe enough stage to reveal statistically significant differences in these. The *Sca1*^{154Q/2Q} mice displayed very mild cerebellar pathology even at 39 weeks, restricted to heterotopic PCs, vacuoles in PCs and molecular layer thinning largely confined to the posterior lobules that were not included in the MRS voxel. Therefore, this study demonstrated that the MRS biomarkers are sensitive to very early changes related to neurodegeneration prior to overt pathology.




Fig. 3. Cerebellar taurine vs. total choline concentrations of individual mice at 3 ages.

References: 1. Taroni F & DiDonato S, Nat Rev Neurosci, 5: 641, 2004. 2. Oz et al, Proc ISMRM 2009, p.541. 3. Watase et al, Neuron, 34: 905, 2002. 4. Garwood & DelaBarre, J Magn Reson, 153: 155, 2001. 5. Provencher SW, MRM, 30: 672, 1993. 6. Henry et al, MRM, 55: 250, 2006.

Supported by NIH R21 NS060253, P41 RR008079, P30 NS057091 and Keck Foundation.




Fig. 1. ^1H MRS spectra from a WT and a *Sca1*^{154Q/2Q} mouse at 24 weeks of age. The voxel positions are shown on T₂-weighted mid-sagittal images.




Fig. 2. Progression of select neurochemical alterations with disease. Number of mice in each group were N = 8-9 at 6 weeks, 8 at 12 weeks, 5-6 at 24 weeks and 2-4 at 39 weeks. Error bars represent SEM.